Global qPCR and dPCR market to reach USD 8.4B by 2030

Reportlinker.com announces the release of the report “Global Real-time PCR (qPCR) and Digital PCR (dPCR) Industry”.

Quantitative, one of the segments analyzed in the report, is projected to record 5.9% CAGR and reach US$7.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Digital segment is readjusted to a revised 9.9% CAGR for the next 8-year period.

The U.S. market is estimated at $1.4 billion, while China is forecast to grow at 10.2% CAGR
The Real-time PCR (qPCR) and Digital PCR (dPCR) market in the U.S. is estimated at US$1.4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.3% and 6.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Select competitors (Total 32 featured)

• Abbott Laboratories
• Agilent Technologies, Inc.
• Analytik Jena AG
• Becton Dickinson and Company
• Bio Molecular Systems
• Biomeme Inc.
• Biomérieux S.A.
• Bioneer Corporation
• Bio-Rad Laboratories, Inc.
• Cole-Parmer Instrument Company Llc
• Danaher Corporation
• Elitech Group Sas
• Enzo Life Sciences, Inc.
• Eppendorf AG
• F. Hoffman-La Roche Ltd.
• Fluidigm Corporation
• JN Medsys
• Merck KGaA
• Meridian Bioscience, Inc.
• Promega Corporation
• Qiagen N.V.
• Quanta Biosciences Inc.
• Sacace Biotechnologies Srl
• Takara Bio, Inc.
• Thermo Fisher Scientific, Inc.

ReportLinker